OMRX Orthometrix Inc (CE)

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2008

OR

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 0-26206

Orthometrix, Inc.

(Exact name of registrant as specified in its charter)

Delaware		06-1387931
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
106 Corporate Park Drive, Suite 102, White Plains, NY		10604
(Address of principal executive office)		(Zip Code)

Registrant’s telephone number, including area code (914) 694-2285

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  þ  Yes    o  No

     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  o  Yes      þ  No

There were 49,638,896 shares of common stock outstanding as of October 30, 2008.

 

 

TABLE OF CONTENTS

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

Consolidated Balance Sheets

		September 30, 2008				December 31, 2007
		(Unaudited)
Assets
Current assets:
Cash		$	2,332			$	27,077
Accounts receivable — trade			17,047				144,972
Other receivable			35,565				—
Inventories			473,844				548,047
Prepaid expenses			9,500				7,792
Total current assets			538,288				727,888
Property and equipment, net			31,893				53,202
Deferred financing costs, net			—				1,388
Other			11,658				11,658
Total Assets		$	581,839			$	794,136
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable — trade		$	1,154,634			$	1,351,830
Accrued expenses			175,409				167,986
Customer deposits			64,747				64,747
Related party loans			263,126				115,000
Notes payable related party, net of discount			2,340,973				1,843,517
Unearned service revenue			77,224				68,649
Loan payable — equipment			4,198				13,971
Total current liabilities			4,080,311				3,625,700
Long term loan payable — equipment			6,574				14,147
Long term notes payable — related party			—				20,000
Total long term liabilities			6,574				34,147
Stockholders’ deficit:
Common stock — par value $.0005 per share, 75,000,000 shares authorized, 49,638,896 and 45,908,618 shares issued and outstanding, respectively			24,818				22,953
Preferred stock — par value $.0005 per share, 1,000,000 shares authorized			—				—
Additional paid-in capital			44,204,948				44,029,964
Accumulated deficit			(47,734,812	)			(46,918,628	)
Total stockholders’ deficit			(3,505,046	)			(2,865,711	)
Total Liabilities and Stockholders’ Deficit		$	581,839			$	794,136

See notes to consolidated financial statements.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

Consolidated Statements of Operations (Unaudited)

		For The Nine Months Ended
		September 30,				September 30,
		2008				2007
Revenue		$	720,036			$	1,672,883
Cost of revenue			468,370				942,046
Gross profit			251,666				730,837
Sales and marketing expense			325,411				651,521
General and administrative expense			496,895				508,993
Research and development expense			684				5,990
Operating loss			(571,324	)			(435,667	)
Interest expense			(254,381	)			(490,912	)
Interest income			666				447
Other income (expense)			8,855				(6,723	)
Net loss		$	(816,184	)		$	(932,855	)
Basic and diluted weighted average shares			47,654,527				45,205,211
Basic and diluted loss per share:
Net loss		$	(0.02	)		$	(0.02	)

See notes to consolidated financial statements.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

Consolidated Statements of Operations (Unaudited)

		For The Three Months Ended
		September 30,				September 30,
		2008				2007
Revenue		$	130,130			$	726,417
Cost of revenue			117,537				384,831
Gross profit			12,593				341,586
Sales and marketing expense			104,890				183,738
General and administrative expense			147,901				166,977
Research and development expense			—				579
Operating loss			(240,198	)			(9,708	)
Interest expense			(70,102	)			(129,587	)
Interest income			—				19
Other income (expense)			642				(6,723	)
Net loss		$	(309,658	)		$	(145,999	)
Basic and diluted weighted average shares			49,638,896				45,257,531
Basic and diluted loss per share:
Net loss		$	(0.01	)		$	(0.00	)

See notes to consolidated financial statements.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

Consolidated Statements of Cash Flows (Unaudited)

		For The Nine Months Ended
		September 30,				September 30,
		2008				2007
Cash Flows From Operating Activities:
Net loss		$	(816,184	)		$	(932,855	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock issued as compensation			27,103				—
Stock options and warrants issued as compensation			79,341				90,744
Loss on sale of equipment			4,028				6,723
Amortization expense of note payable discounts			44,937				332,862
Amortization expense of deferred financing costs			1,388				11,102
Depreciation expense			12,781				15,812
Changes in assets and liabilities:
Decrease in accounts receivable			127,925				97,756
Increase in other receivable			(35,565	)			—
Decrease in inventories			74,203				121,023
(Increase) decrease in prepaid expenses			(1,708	)			16,041
Decrease in accounts payable			(197,196	)			(52,751	)
Increase (decrease) in accrued expenses			7,423				(51,443	)
Increase in unearned service revenue			8,575				6,133
Increase in customer deposits			—				48,404
Net cash used in operating activities			(662,949	)			(290,449	)
Cash Flows From Investing Activities:
Net proceeds from sale of equipment			4,500				9,500
Purchases of property and equipment			—				(9,114	)
Net cash provided by investing activities			4,500				386
Cash Flows From Financing Activities:
Proceeds of borrowings from related parties			1,065,126				1,059,402
Repayment of borrowings from related parties			(463,726	)			(391,054	)
Exercise of stock options and warrants			49,650				65
Repayment of line of credit			—				(350,000	)
Repayment of loan payable — equipment			(17,346	)			(22,792	)
Net cash provided by financing activities			633,704				295,621
Net (decrease) increase in cash			(24,745	)			5,558
Cash at beginning of period			27,077				4,011
Cash at end of period		$	2,332			$	9,569
Supplemental disclosure of cash flow information:
Cash paid for interest		$	10,306			$	—
Cash paid for income taxes		$	6,754			$	—

See notes to consolidated financial statements.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.		Basis of Presentation and Going Concern
		The consolidated financial statements of Orthometrix, Inc. and Subsidiary (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10-Q and do not include all of the information and footnote disclosures required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2007, and included in the Company’s Report on Form 10-KSB as filed with the Securities and Exchange Commission on March 21, 2008. In the opinion of management, the accompanying interim unaudited consolidated financial statements contain all adjustments (consisting of normal, recurring accruals) necessary for a fair presentation of the consolidated financial position, results of operations and cash flows for these interim periods.
		During the past two fiscal years ended December 31, 2007 and 2006, the Company has experienced aggregate losses from operations of $3,056,246 and has incurred total negative cash flow from operations of $1,390,003 for the same two-year period. During the nine months ended September 30, 2008, the Company experienced a net loss of $816,184 and a negative cash flow from operating activities of $662,949. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
		The Company’s continued existence is dependent upon several factors including obtaining substantial additional financing, increasing sales volume, achieving profitability on the sale of some products and developing new products. The Company is pursuing initiatives to increase liquidity, including external investments and obtaining lines of credit. In order to increase its cash flow, the Company is continuing its efforts to stimulate sales. The Company has also implemented high credit standards for its customers and is emphasizing the receipt of down payments from customers at the time their purchase orders are received. The Company is also requesting prepayment from customers and attempting to more closely coordinate the timing of purchases with the timing of orders for products.
		The results of operations for the nine months ended September 30, 2008 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2008.
2.		Inventories
		As of September 30, 2008, inventories consisted of $473,844 of sub-assemblies, parts, spare parts and finished goods. During the nine months ended September 30, 2008, the Company wrote down the value of its spare parts in excess of on-hand inventory by $66,000.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

3.		Income Taxes
		The Company accounts for deferred income taxes by recognizing the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. The effect of a change in tax rates on deferred taxes is recognized in income in the period that includes the enactment date. The Company realizes an income tax benefit from the exercise of certain stock options or the early disposition of stock acquired upon exercise of certain options. This benefit results in an increase in additional paid in capital. Realization of the deferred tax asset is dependent on the Company’s ability to generate sufficient taxable income in future periods. Based on the Company’s existing financial condition, the Company determined that it was more likely than not that the deferred tax assets would not be realized. Accordingly, the Company recorded a valuation allowance to reduce the deferred tax assets to zero.
4.		Contingency
		The Company leases its corporate office space located in White Plains, New York. Effective August 1, 2003, the Company amended its lease for office space which expired on July 31, 2008. The Company did not renew its corporate office lease on July 31, 2008, but it has been extended on a month to month basis at $2,632 per month.
5.		Related Party Transactions
		As of September 30, 2008, related party debt consists of:

						Interest Rate
Loans payable		$	263,126				6	%
Notes payable, net of discount			2,340,973				6% - 12	%
Total related party debt		$	2,604,099

		For all of the notes, the Company is obligated to prepay the principal amount within 10 days upon the occurrence of either of two events; if it (i) receives at least $5,000,000 from an equity financing or (ii) sells substantially all of its assets.
		During the nine months ended September 30, 2008, the Company issued notes and loans payable to related parties of $1,065,126. In conjunction with the notes payable, 535,000 warrants were issued. The warrants issued were valued at $20,755. These warrants were valued using the Black-Scholes option pricing model, and recorded as a discount to the notes payable and a credit to additional paid in capital. At September 30, 2008, the unamortized discount on the notes payable is $5,301. During the nine months ended September 30, 2008 and 2007, amortization of the notes payable discounts of $44,937 and $332,862 was recorded as interest expense, respectively. During the nine months ended September 30, 2008, the Company repaid notes and loans payable to related parties of $463,726.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

5.		Related Party Transactions (Continued)
		Interest expense for the nine months ended September 30, 2008 and 2007, in relation to related party loans and notes payable amounted to $207,013 and $152,191, respectively.
		During the nine months ended September 30, 2008, the Company’s board of directors approved a grant of stock options to Mr. Reynald Bonmati to purchase an aggregate of 3,998,750 shares, of its common stock with exercise prices equal to or greater than the market price of stock on the date of grant. The options are 5-year options (Mr. Bonmati is a 10% shareholder) and vest over four years. The fair value of these issuances was estimated using the application of the Black-Scholes option pricing model. During the nine months ended September 30, 2008, $54,681 of non-cash compensation was recorded as consulting fees and additional paid-in capital. Mr. Bonmati’s salary was waived for the nine months ended September 30, 2008.
6.		Stock-Based Compensation
		During the nine months ended September 30, 2008, the Company’s board of directors approved a grant of stock options to employees, directors and independent consultants to purchase an aggregate of 4,566,250 shares of its common stock (which includes the amount described in Note 5) with exercise prices equal to or greater than the market price of stock on the date of grant. The options are 10-year options (with the exception of Mr. Bonmati, a 10% shareholder, whose options expire in 5 years) and vest over 4 years. The fair value of these issuances was estimated using the application of the Black-Scholes option pricing model. During the nine months ended September 30, 2008, $79,342 of non-cash compensation cost was recognized.
7.		Major Customers
		During the nine months ended September 30, 2008, approximately 58.6% of total sales were derived from the Company’s three largest customers.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The matters discussed in this Form 10-Q contain certain forward-looking statements and involve risks and uncertainties (including changing market conditions, competitive and regulatory matters, etc.) detailed in the disclosure contained in this Form 10-Q and the other filings with the Securities and Exchange Commission made by the Company from time to time. The discussion of the Company’s liquidity, capital resources and results of operations, including forward-looking statements pertaining to such matters, does not take into account the effects of any changes to the Company’s operations. Accordingly, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including those identified herein. This item should be read in conjunction with the financial statements and other items contained elsewhere in the report.

Critical Accounting Policies and Estimates

The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States. These accounting principles require management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements as well as the reported amount of revenues and expenses during the periods presented. Estimates are used when accounting for the allowance for uncollectible receivables, potentially excess and obsolete inventory, depreciation and amortization, warranty reserves, income tax valuation allowances and contingencies, among others. Actual results could differ significantly from those estimates. The Company believes that the estimates, judgments and assumptions upon which the Company rely are reasonable based upon information available at the time.

The Company believes the following accounting policies involve additional management judgment due to the sensitivity of the methods, assumptions and estimates necessary in determining the related asset and liability amounts. The Company sells its products directly to customers and through third-party dealers and distributors. Revenue is recognized at the time products are shipped and title passes to the customer. The Company estimates and records provisions for product installation and user training in the period that the sale is recorded.

In the United States and Canada, the Company offers one-year warranties on both the hardware and software included in its systems (except for computer systems, if any, which are covered under their respective manufacturers’ warranty), as well as extended warranty contracts. Outside of the United States and Canada, the Company only offers one-year warranties on parts; the labor warranty is provided by the Company’s distributors. The Company also offers six-month warranties on replacement parts worldwide. The Company provides warranty services to its customers in the United States and Canada. Any costs incurred by the Company in connection with a warranty of a system are borne by the manufacturer pursuant to the applicable distribution agreement. Therefore, no warranty reserve is required by products sold by the Company.

The Company has no obligations to provide any other services to any of its third party dealers or distributors or their customers.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued)

Critical Accounting Policies and Estimates (Continued)

The Company provides estimated inventory allowances for slow-moving and obsolete inventory based on current assessments about future demands, market conditions and related management initiatives. If market conditions are less favorable than those projected by management, additional inventory allowances may be required.

The Company provides allowances for uncollectible receivable amounts based on current assessment of collectability. If collectability is less favorable than those projected by management, additional allowances for uncollectability may be required.

The Company accounts for deferred income taxes by recognizing the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. The effect of a change in tax rates on deferred taxes is recognized in income in the period that includes the enactment date. The Company realizes an income tax benefit from the exercise of certain stock options or the early disposition of stock acquired upon exercise of certain options. This benefit results in an increase in additional paid in capital.

Liquidity and Capital Resources

The Company has financed operations for the past five years through the sale of equity securities and the issuance of debt. For the two years ending December 31, 2007 and 2006, the Company incurred aggregate net losses of $3,056,246 and negative cash flow from operations of $1,390,003. During the nine months ended September 30, 2008, the Company incurred a net loss of $816,184 and negative cash flow from operations of $662,949. As of September 30, 2008, the Company had $2,332 in unrestricted cash available for working capital purposes. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

The Company’s continued existence is dependent upon several factors including obtaining substantial additional financing, increasing sales volume, achieving profitability on the sale of some products and developing new products. However, in order to increase cash flow, the Company is continuing its efforts to stimulate sales. In order to manage credit risk, the Company has begun to implement higher credit standards for customers and to emphasize the receipt of down payments from customers at the time their purchase orders are received. The Company has also begun to request more prepayments from customers and attempt to more closely coordinate the timing of purchases with the timing of orders for products. The Company cannot predict whether or to what extent these risk management functions may slow its ability to grow revenues.

The level of the Company’s cash decreased to $2,332 at September 30, 2008 from $27,077 at December 31, 2007. The Company had net cash used in operating activities of $662,949 for the nine months ended September 30, 2008 which was substantially offset by $633,704 in net cash provided by financing activities and $4,500 of cash provided by investing activities. Financing activities consisted of

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued)

Liquidity and Capital Resources (Continued)

$1,065,126 in loans from related parties and $49,650 of proceeds received from the exercise of stock options and warrants, which were partially offset by the repayment of equipment loan payable of $17,346 and repayment of borrowings of $463,726 from related parties. Investing activities consisted of $4,500 of net proceeds received from the sale of equipment.

For all of the notes, the Company is obligated to prepay the principal amount within 10 days upon the occurrence of either of two events; if it (i) receives at least $5,000,000 from an equity financing or (ii) sells substantially all of its assets.

During the nine months ended September 30, 2008, the Company’s board of directors approved a grant of stock options to employees, directors and independent consultants to purchase an aggregate of 4,566,250 shares of its common stock with exercise prices equal to or greater than the market price of stock on the date of grant. The options are 10-year options (with the exception of Mr. Bonmati, a 10% shareholder, whose options expire in 5 years) and vest over 4 years. The fair value of these issuances was estimated using the application of the Black-Scholes option pricing model. During the nine months ended September 30, 2008, $79,342 of non-cash compensation cost was recognized as non-cash compensation expense and additional paid-in capital.

The Company had no backlog of orders as of September 30, 2008 and there are no material commitments for capital expenditure as of that date. The Company believes that they will need to raise substantial additional capital within the next twelve months in order to support the planned growth of the business. The Company may seek additional funding through collaborative arrangements and public or private financings. Additional funding may not be available on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. For example, if the Company raises additional funds by issuing equity securities, further dilution to existing stockholders may result. The Company also could be required to seek funds through arrangements with collaborators or others that may require the Company to relinquish rights to some of their technologies, product candidates or products which they would otherwise pursue on their own.

Star Trac Health & Fitness, Inc. (“Star Trac”), a leading provider of exercise equipment to the commercial and retail fitness markets, entered into a licensing agreement with the Company. Star Trac acquired from the Company a non-exclusive license to design, manufacture, market and service worldwide whole body vibration devices using the same patented technology that the Company uses for its VibraFlex® whole body vibration systems. Style for Life, Inc., a provider of fitness and wellness products and services, acquired from the Company a non-exclusive license to design and manufacture worldwide, and to market and service in the United States, Canada and Mexico, whole body vibration devices using the same patented technology that the Company uses for its VibraFlex® whole body vibration systems.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued)

Results of Operations

The Company had a net loss of $816,184 ($0.02 per share based on 47,654,527 weighted average shares) for the nine months ended September 30, 2008 compared to net loss of $932,855 ($0.02 per share based on 45,205,211 weighted average shares) for the nine months ended September 30, 2007.

Revenue for the nine months ended September 30, 2008 decreased $952,847 (or 57.0%) to $720,036 from $1,672,883 from the comparable period of fiscal 2007. The decrease in revenue was primarily due to a decrease in VibraFlex Ò and XCT system sales during 2008.

Cost of revenue as a percentage of revenue was 65.0% and 56.3% for the nine months ended September 30, 2008 and 2007, respectively, resulting in a gross profit of 35.0% for the nine months ended September 30, 2008 compared to 43.7% for the comparable period of 2007. The decrease in gross profit was due to the strength of the Euro and a weak dollar, which creates the cost of products to rise.

Sales and marketing expense for the nine months ended September 30, 2008 decreased $326,110 (or 50.1%) to $325,411 from $651,521 for the nine months ended September 30, 2007. The decrease is due to the Company’s decrease in sales staff to market and sell the Orbasone™ and decreased trade show and travel expenses to market the Orbasone™.

General and administrative expense for the nine months ended September 30, 2008 decreased $12,098 (or 2.4%) to $496,895 from $508,993 for the nine months ended September 30, 2007. The decrease was due to a reduction of insurance expenses incurred by the Company.

Interest expense decreased $236,531 (or 48.2%) to $254,381 for the nine months ended September 30, 2008 from $490,912 for the nine months ended September 30, 2007. Interest expense decreased primarily due to a reduction in the amortization expense of note payable discounts.

Recently Issued Accounting Pronouncements

In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities” (“SFAS No. 161”). The new standard is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity’s financial position, results of operations and cash flows. SFAS No. 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. The Company does not expect this standard to have a material impact on its financial position, results of operations or cash flows.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Continued)

Recently Issued Accounting Pronouncements (Continued)

In May 2008, the FASB issued SFAS No. 162, “The Hierarchy of Generally Accepted Accounting Principles” (“SFAS 162”). SFAS 162 identifies the sources of accounting principles and the framework for selecting the principles used in the preparation of financial statements that are presented in conformity with generally accepted accounting principles (“GAAP”) in the United States. SFAS 162 will become effective 60 days following the SEC’s approval of the Public Company Accounting Oversight board amendments to AU Section 411, “The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles”. The Company does not expect the adoption of SFAS 162 to have a material impact on its financial position, results of operations or cash flows.

Item 3. Quantitative and Qualitative Disclosures of Market Risk

The Company does not have any financial instruments that would expose it to market risk associated with the risk of loss arising from adverse changes in market rates and prices.

All of the Company’s loans payable outstanding at September 30, 2008 have variable interest rates and therefore are subject to interest rate risk. A one percent change in the variable interest rate would result in a $26,199 change in annual interest expense.

Item 4T. Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures are effective.

There has been no change in the Company’s internal controls over financial reporting during the Company’s third quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal controls over financial reporting.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

PART II — OTHER INFORMATION

Item 6. Exhibits

31.1		Chief Executive Officer’s Certification, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Chief Financial Officer’s Certification, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32		Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

ORTHOMETRIX, INC.
FORM 10-Q SEPTEMBER 30, 2008

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Orthometrix (CE) (USOTC:OMRX)
Historical Stock Chart
From May 2024 to Jun 2024

Orthometrix (CE) (USOTC:OMRX)
Historical Stock Chart
From Jun 2023 to Jun 2024